What if the next major artificial intelligence opportunity is taking shape inside medicine rather than another chatbot boom? 

True Innovations Report follows Josh Baylin’s research into Medical AI, where specialized AI systems could speed up drug discovery and create opportunities across the companies supporting this shift. 

In this True Innovations Report review, I’ll look at what Stansberry Research is offering, why Baylin is looking beyond a single AI stock idea, and whether the strategy deserves your attention.

>> Get Josh Baylin’s True Innovations Report <<

What Is True Innovations Report?

True Innovations Report is a monthly research service from Stansberry Research that focuses on major technology trends and the stocks positioned to benefit from them. 

Josh Baylin leads the service alongside senior analyst John Engel, with coverage spanning artificial intelligence, robotics, cybersecurity, biotech, cloud computing, and other fast-moving industries.

Members receive a new issue each month featuring market analysis and at least one fresh recommendation tucked inside. 

The subscription also includes ongoing buy and sell alerts, a model portfolio that tracks current positions, access to past research, and complimentary access to the Stansberry Digest. 

I try my best to get ahead of a tech breakout any chance I can, since we’ve all seen what the space can do for potentially generating wealth. This feels like an excellent way to do just that.

It makes me very curious about what’s happening with “Medical AI”, but I am not as familiar with Josh, so I wanted to catch up on his story first.

>> Join Josh Baylin’s True Innovations Report <<

Who Is Josh Baylin?

Josh Baylin is a technology-focused analyst with more than 20 years of experience across financial markets, media, data, and automation. 

His career began at Bloomberg News in Washington, D.C., where he covered technology and public policy. 

Baylin later moved into finance with a role at SAC Capital, where his work involved helping manage more than $200 million.

He also launched a quantitative fund and built a golf analytics business covering more than 15,000 courses. 

Baylin later joined robotics company Brain Corp in a senior product, marketing, and analytics role.

Today, he brings that mix of finance, technology, and quantitative research to Stansberry Research as editor of True Innovations Report.

Is Josh Baylin Legit?

Absolutely. Josh Baylin has earned credibility by recognizing major technology shifts well before they became obvious.

In 2004, he testified before Congress about phones, cameras, music players, and other functions converging into a single mobile device. 

Three years later, Apple introduced the iPhone.

Baylin then made Apple his top idea at SAC Capital in 2007 and predicted the iPhone could eventually sell one billion units. 

That forecast sounded aggressive at the time, but Apple ultimately surpassed it.

His technology experience also extends beyond market research. 

At Brain Corp, Baylin helped support the growth of an autonomous robotics platform that has since expanded to more than 50,000 machines across six continents today.

That combination of early calls and hands-on experience lends real weight to his emerging-technology research.

>> Access True Innovations Report Today <<

What Is Sam Altman’s Next Venture? Josh Baylin’s Medical AI Investment Case

Few would argue that medical research has improved by leaps and bounds over the last 100 years.

Sam Altman believes we’ve slammed into a roadblock, though, and the old way of doing things just doesn’t cut it anymore.

Drug discovery still takes 10 to 15 years, costs more than $2 billion per drug, and fails more than 90% of the time. 

In a sobering thought, the World Health Organization warns that these infections could kill 10 million people per year by 2050 if the pace does not improve. 

Josh Baylin believes Medical AI can speed up the search for new treatments and create a financial opportunity around the companies helping make those discoveries possible.

The Old Biotech Model Is Running Out of Time

The traditional process is still built around testing huge numbers of molecules and hoping one eventually works. 

Spending on medical research has risen about 80-fold since 1950, yet the basic success rate has barely improved. 

Capital has started pulling away from that model as well. 

Old-school biotech IPOs have fallen nearly 90%, more than 200 public biotech companies have disappeared in four years, and venture funds backing new biotech firms are raising 92% less money than at their peak.

The FDA estimates that fewer than 10% of known rare diseases have a cure. Antibiotic resistance adds another layer of pressure because bacteria do not wait for ten-year research cycles.

A system that can shorten the earliest stages of drug discovery from years to hours would change both the medical and financial side of the equation.

>> Unlock Josh Baylin’s Medical AI Research <<

Sam Altman Is Putting Money Behind Medical AI

Specialized AI systems are already being used to search for medicines in ways conventional research cannot match.

MIT researchers used Medical AI to identify an entirely new class of potential antibiotics against drug-resistant bacteria. 

The system could generate hundreds of thousands of candidates in roughly three hours, which Baylin estimates is about 10,000 times faster than traditional human-led discovery. 

In Scotland, AI screened more than 4,000 molecules tied to aging, found 21 promising candidates in five minutes, and helped narrow the list to three.

This is already moving beyond computer models. Rentosertib, an AI-discovered drug for pulmonary fibrosis, is being tested in patients. 

Medical AI is already in the works, whether you like it or not. The cool thing, though, is that we’re just in the beginning stages of something that could forever change how we diagnose and treat disease.

The Better Bet May Be the Companies Supporting the Drugs

This is where Josh Baylin comes in. He says there’s a lot of opportunities for money to be made here, and I’m very inclined to believe him.

Every treatment needs companies that manufacture it, preserve it, transport it, and provide specialized components along the way.

Medical AI could increase the number of drug candidates moving through those same manufacturing and logistics networks. 

That provides a clear path to participate in the trend without relying on a single biotech company to produce the winning treatment.

Josh Baylin’s specific stock ideas tied to this  Medical AI theme are available through True Innovations Report, so you’ll need to subscribe to access the research. 

Next, I’ll look at what comes with the service.

>> See Josh Baylin’s Latest Stock Picks <<

What You Get With True Innovations Report: Issues, Portfolio, and Alerts

The membership is built around ongoing access to Josh Baylin and John Engel’s research. Let’s see what that entails:

12 Months of True Innovations Report

The main subscription includes 12 months of True Innovations Report.

Each month, Josh Baylin and Senior Analyst John Engel publish a new issue with detailed market analysis and their latest stock recommendations.

Baylin brings the perspective of someone who helped manage $200 million at a major fund, while Engel adds deep biotech knowledge from his background in drug research. 

These gentlemen focus on stocks they believe most people overlook, especially in fast-moving technology areas.

Despite their knowledge and an innovative sector, I think most folks will have no trouble understanding the concepts in the newsletter and put the suggestions to action if they so choose.

>> Start True Innovations Report Today <<

24/7 Access to the True Innovations Report Model Portfolio

You can access the True Innovations Report model portfolio at any time, giving a view of Josh Baylin and his team’s current buy and sell recommendations throughout the year.

That makes it easier to see which ideas are still active, which positions have changed, and where the team currently stands without digging through old issues or emails. 

I frequently use it as a reference point to see how stocks are moving and gauge the life of the service overall.

Baylin and his team continue monitoring their ideas after publication, so the portfolio helps you stay aligned with the research as market conditions and company fundamentals change.

True Innovations Report Digital Archive: 100+ Back Issues

Another really cool feature is the large digital archive containing more than 100 back issues of True Innovations Report.

It stretches back years and gives you access to past research across a wide range of investment themes all in one place. 

That includes earlier ideas tied to technology, AI, biotech, robotics, and other major market trends the service has followed over time.

I would not treat every old recommendation as a current buy, the current buy recommendations are in the model portfolio but the archive has real value as a research library. 

It lets you see how earlier investment ideas were developed, what catalysts the team was watching, and how certain trends evolved.

>> Claim True Innovations Report Access <<

Buy and Sell Alerts

Josh Baylin and his team send email updates throughout the month whenever a portfolio position requires attention.

These alerts let you know when the team believes it is time to lock in potential gains, add to an existing position, close a holding, or respond to an important new development. 

News doesn’t follow newsletter cycles, so having this information when you need it is a huge win.

Plus, you can stay current on positions without constantly monitoring every company by yourself, which speaks volumes to me. 

Dedicated U.S.-Based Customer Support

Finally, there’s Stansberry Research’s Customer Care team to help with issues.

The support operation is U.S.-based and available Monday through Friday from 9 a.m. to 5 p.m. Eastern Time.

Nothing is outsourced, and you have a direct contact for account access, subscription questions, billing issues, renewals, cancellations, and other membership concerns.

It may sound like a small feature compared with the stock research, but reliable customer support matters with any paid financial subscription. 

If you have a problem accessing your research or need to make a change to your membership, you know exactly where to go and when someone will be available to help.

>> Explore Josh Baylin’s Medical AI Picks <<

True Innovations Report Bonus Reports: Medical AI, Robotics, and Stocks to Avoid

The new-member package adds four research reports plus two ongoing resources. 

Together, they expand the service beyond Medical AI into Agentic AI, robotics, weaker AI stocks, daily market commentary, and portfolio risk management.

Featured Report: Sam Altman’s Next Venture: How to Profit From the Convergence of AI and Medicine

Josh Baylin uses his research to identify the stocks he believes could benefit as artificial intelligence moves deeper into medicine. 

The strategy focuses on companies that could support AI-driven drug discovery through manufacturing, storage, transportation, specialized components, and other essential services. 

That gives each of us another route into the trend without relying on one experimental treatment to succeed.

Baylin follows the same supplier-style approach used elsewhere in the research, where companies supporting a major technological shift can sometimes benefit alongside the headline names.

Inside, you’ll get the exact stock recommendations Baylin currently favors for this Medical AI theme, making the report the most direct way to act on the Sam Altman opportunity discussed earlier.

>> Get True Innovations Report Now <<

Bonus Report #1: The Agent Economy: Stocks Set to Soar in AI’s Next Phase

The Agent Economy covers the shift from AI that simply responds to prompts toward systems capable of using tools, completing tasks, and handling more complex work with less human input.

OpenAI has reported that one of its newer models played an important role in its own creation, underscoring how quickly the technology is advancing.

Baylin also traces the rapid jump in capabilities from basic math problems in 2022 to passing the bar exam in 2023 and writing advanced software by 2024. 

Anthropic’s CEO has warned that AI could eventually replace a large share of entry-level white-collar jobs.

The report gives members Baylin’s preferred stocks in companies positioned for the next stage of AI adoption.

Bonus Report #2: The Winners of the AI Robot Revolution

Robotics is an area where Baylin brings direct operating experience. 

He previously helped lead Brain Corp, which supplied autonomous robotics technology to major companies such as Walmart and Sam’s Club and has since grown to power more than 50,000 robots across six continents today.

The numbers around the wider robotics market are already substantial. 

Around 750,000 AI-powered robots are working in warehouses, while robotic systems have assisted in roughly 12 million surgeries and now take part in more than one-fifth of U.S. surgical procedures.

Elon Musk plans to build 1 million Optimus robots per year, while Nvidia CEO Jensen Huang has called robotics the “Next Wave of AI.” 

You’ll find Baylin’s favorite stocks for the rise of the machines here and all the info you need to play them.

>> Follow Josh Baylin’s Technology Research <<

Bonus Report #3: AI Stocks to Avoid

AI Stocks to Avoid looks at the other side of the artificial intelligence boom. Sadly, not every stock related to the trend will succeed.

Just like in the dot-com era, Amazon became one of the biggest winners of the Internet boom, while companies such as Pets.com disappeared entirely.

Baylin expects a similar divide in AI. Some companies may carry an attractive AI story but lack the technology, financial strength, or competitive position to survive as the industry matures.

This guide hosts the list of popular AI stocks Baylin believes you should avoid, including names he says existing shareholders may want to sell.

Bonus Daily Research: Stansberry Digest

Subscribers also receive complimentary access to Stansberry Digest, one of Stansberry Research’s longest-running publications.

The Digest arrives every trading day rather than once a month and includes market analysis from a rotating group of 20 financial minds across the firm.

That gives access to broader market coverage between issues of True Innovations Report. 

While Baylin and John Engel concentrate on technology, AI, biotech, and other emerging themes, the Digest can cover developments affecting the wider stock market and economy.

I see it as a useful way to stay informed between portfolio alerts without needing to add another daily research subscription.

Complimentary Bonus: TradeStops Basic

It’s currently possible to snag a complimentary one-year membership to TradeStops Basic, a portfolio-monitoring tool designed to make risk management more systematic.

TradeStops can connect with a brokerage account for real-time tracking and help calculate position sizes based on personalized risk levels.

Its Volatility Quotient, or VQ, measures how much an individual stock normally moves and uses that information to create data-driven exit levels. 

The goal is to help you avoid making sell decisions based on fear during ordinary market swings.

I’d recommend taking it even though it’s not the crux of the service, as it can help take the emotion out of your decisions.

>> Join True Innovations Report Today <<

True Innovations Report 30-Day Money-Back Guarantee

True Innovations Report comes with a 30-day, 100% money-back guarantee. 

You can access the service, research, portfolio, and new-member bonuses during that period, then decide whether it meets your expectations. 

If you cancel within the first 30 days for any reason, you’ll receive a full cash refund of your membership fee.

You’ll even get to keep any materials you’ve collected so far, which is a nice touch.

True Innovations Report Pros and Cons

After reviewing True Innovations Report, these are the standout strengths and the few softer drawbacks I found.

>> Discover Josh Baylin’s Medical AI Strategy <<

True Innovations Report Track Record and Past Performance

True Innovations Report has been around since 2018, and its past results include several standout wins across major technology trends. 

Since then, readers have had early exposure to cryptocurrency, with gains of 574% on Bitcoin and 652% on Ethereum. 

There were also gains of 851% on Lumentum and 1,183% on Ciena.Both earned spots in Stansberry Research’s “Hall of Fame” for some of the firm’s biggest historical gains.

The broader record is also worth noting. Since inception, the average gain for True Innovations Report is 55.8%. 

Those numbers are impressive, but they do all come straight from the publisher.

Still, the mix of large historical gains and a positive average return gives the service a stronger track record than a newsletter built around untested ideas alone.

>> Unlock True Innovations Report Research <<

How Much Does True Innovations Report Cost?

True Innovations Report normally costs $499 per year, but the current deal cuts $370 off that rate, bringing the first-year cost down to $129, or about 35 cents per day.

That price includes 12 monthly issues, the model portfolio, buy-and-sell alerts, more than 100 archived issues, Stansberry Digest access, the four AI-focused research reports, and the optional one-year TradeStops Basic membership. 

From where I’m sitting, that’s a lot of content for one low price.After the first year, the subscription automatically renews at $199 annually, plus applicable taxes, unless you cancel before the renewal date. 

>> Get Josh Baylin’s Latest Research <<

Is True Innovations Report Worth It?

I think True Innovations Report does well at identifying tech movers before they come into the spotlight, providing opportunities you’ll likely not hear elsewhere.

Josh Baylin brings experience across finance, robotics, and emerging tech, while Stansberry Research adds the structure of monthly issues, portfolio updates, and ongoing alerts.

The “larger than ChatGPT” claim around Medical AI is bold, but any big shakeups in this space could lead to impressive returns.

I’d advise thinking beyond this one concept though, since True Innovations Report offers quite a bit more.

At $129 for the first year, the value is off the charts. Don’t forget you’ve got that first month to request a refund if you find something you don’t like.

If you’ve been on the sidelines of AI-based tech disruptions, sign up before these Medical AI opportunities are too far gone.

>> Get True Innovations Report Membership <<